Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Novavax Inc.
NVAX : NASDAQ : Health Care

$2.00 0.02 | 1.01%
Today's Range: 1.97 - 2.02
Avg. Daily Volume: 1,423,400
05/21/13 - 10:40 AM ET

Financial Analysis


NOVAVAX INC's gross profit margin for the first quarter of its fiscal year 2013 has significantly increased when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the industry, the net income growth did not.



Income Statement Q1 FY13 Q1 FY12
Net Sales ($mil)3.834.64
EBITDA ($mil)0.0-7.06
EBIT ($mil)-10.01-7.47
Net Income ($mil)-9.98-7.34


Balance Sheet Q1 FY13 Q1 FY12
Cash & Equiv. ($mil)0.020.72
Total Assets ($mil)98.768.64
Total Debt ($mil)1.960.41
Equity ($mil)0.054.32


Profitability Q1 FY13 Q1 FY12
Gross Profit Margin55.3427.14
EBITDA Margin0.0-152.15
Operating Margin-261.02-160.86
Sales Turnover0.220.27
Return on Assets-31.55-28.04
Return on Equity0.0-35.43
Debt Q1 FY13 Q1 FY12
Current Ratio5.593.37
Debt/Capital0.00.01
Interest Expense0.00.0
Interest Coverage0.0-2489.0


Share Data Q1 FY13 Q1 FY12
Shares outstanding (mil)147.94122.11
Div / share0.00.0
EPS-0.07-0.06
Book value / share0.00.44
Institutional Own % n/a n/a
Avg Daily Volume1413960.0671106.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
NVAX NM Peers 32.50   NVAX NA Peers 48.70

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

NVAX's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
NVAX NM Peers 31.25   NVAX NA Peers 0.70

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

NVAX's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
NVAX NA Peers 9.88   NVAX -43.75 Peers 5.98

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

Ratio not available.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, NVAX is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
NVAX 14.34 Peers 513.82   NVAX 14.98 Peers 69.95

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

NVAX is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

NVAX significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades

Brokerage Partners


Top Rated Stocks Top Rated Funds Top Rated ETFs